Pfizer has announced the launch of its competitors to Roche’s ‘big three’ cancer drugs in the US, at a “substantially discounted price” compared with the originators.
For several years AstraZeneca has been selling off rights to its older drugs to raise cash as it develops a new generation of drugs, and this pattern has continued as it sold its Arimidex a
AstraZeneca had to ask shareholders for $3.5 billion in extra cash to finance an R&D tie-up with Daiichi Sankyo for an experimental breast cancer drug – and so far it looks like money w
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.